EIN 85-1085804

Phare Bio

IRS 501(c) type
501(c)(3)
Num. employees
3
City
Year formed
2020
Most recent tax filings
2023-06-01
Description
Phare Bio uses AI/deep learning to develop novel antibiotics to tackle antimicrobial resistance. Its mission is to rapidly discover and develop new classes of antibiotics against the deadliest infections using AI and deep learning approaches. The company has promising early-stage pipeline projects and conducts extensive in vitro and in vivo drug development.
Total revenues
$2,009,513
2023
Total expenses
$1,249,510
2023
Total assets
$1,837,494
2023
Num. employees
3
2023

Program areas at Phare Bio

Phare Bio's program mandate is to develop critically needed antibiotics to address a looming crisis in antibiotic resistance. Phare Bio has a number of promising early-stage pipeline projects and is conducting extensive in vitro and in vivo drug development studies to advance potential antibiotics through the research and development process. These antibiotic candidates are discovered via a novel ai/deep learning platform developed by professor jim collins' lab at mit (Phare Bio's ai discovery partner and co-founder) and optimized for future clinical application at Phare Bio. With this cutting-edge platform and a nonprofit business model, Phare Bio is developing new classes of antibiotics and uniquely addressing economic challenges facing the antibiotic market. In this past year, Phare Bio incorporated generative ai into its discovery platform, further enhancing its early-stage pipeline of novel antibiotics.

Who funds Phare Bio

Grants from foundations and other nonprofits
GrantmakerDescriptionAmount
Schwab Charitable FundHealth$500,000
Fidelity Investments Charitable Gift FundFor Grant Recipient's Exempt Purposes$357,143
Fidelity Investments Charitable Gift FundFor Grant Recipient's Exempt Purposes$357,143
...and 2 more grants received

Personnel at Phare Bio

NameTitleCompensation
Akhila KosarajuChief Executive Officer and President$531,282
Jonathan M. StokesDirector
William FosterChair$0

Financials for Phare Bio

RevenuesFYE 06/2023
Total grants, contributions, etc.$2,007,643
Program services$0
Investment income and dividends$0
Tax-exempt bond proceeds$26
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$0
Net income from fundraising events$0
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$1,844
Total revenues$2,009,513

Form 990s for Phare Bio

Fiscal year endingDate received by IRSFormPDF link
2023-062024-04-17990View PDF
2022-062023-05-04990View PDF
2021-062022-08-12990View PDF
2020-062022-08-26990EZView PDF
2020-062021-09-02990EZView PDF
Data update history
December 23, 2023
Received grants
Identified 1 new grant, including a grant for $200,000 from Hopewell Fund
October 25, 2023
Received grants
Identified 1 new grant, including a grant for $200,000 from American Endowment Foundation
August 29, 2023
Updated personnel
Identified 12 new personnel
August 10, 2023
Posted financials
Added Form 990 for fiscal year 2021
July 22, 2023
Posted financials
Added Form 990 for fiscal year 2022
Nonprofit Types
Medical research organizationsResearch centersCharities
Issues
Science and technologyHealth
Characteristics
Conducts researchPartially liquidatedOperates internationallyState / local levelTax deductible donations
General information
Address
303 Congress St 2nd Floor
Boston, MA 02210
Metro area
Boston-Cambridge-Newton, MA-NH
County
Suffolk County, MA
Website URL
pharebio.org/ 
Phone
(617) 426-5900
IRS details
EIN
85-1085804
Fiscal year end
June
Taxreturn type
Form 990
Year formed
2020
Eligible to receive tax-deductible contributions (Pub 78)
Yes
Categorization
NTEE code, primary
H00: Medical Research: General
NAICS code, primary
5417: Scientific Research and Development Services
Parent/child status
Independent
Free account sign-up

Want updates when Phare Bio has new information, or want to find more organizations like Phare Bio?

Create free Cause IQ account